Sinopep-Allsino Biopharmaceutical Co. Ltd. A (SHG:688076) — Stock Price

CN¥28.16 CNY
▼ -0.46% today

Sinopep-Allsino Biopharmaceutical Co. Ltd. A (SHG:688076) is currently trading at CN¥28.16 CNY, down 0.46% today. Over the past 52 weeks, shares have ranged between CN¥26.25 and CN¥46.88. This page tracks Sinopep-Allsino Biopharmaceutical Co. Ltd. A's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Sinopep-Allsino Biopharmaceutical Co. Lt market cap and net worth.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Sinopep-Allsino Biopharmaceutical Co. Ltd. A's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Income Statement — Revenue, Profit & Earnings by Year

Sinopep-Allsino Biopharmaceutical Co. Ltd. A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue CN¥1.94 Billion CN¥1.62 Billion CN¥1.03 Billion CN¥651.29 Million CN¥643.87 Million
Cost of Revenue CN¥725.75 Million CN¥575.05 Million CN¥444.27 Million CN¥307.94 Million CN¥306.30 Million
Gross Profit CN¥1.94 Billion CN¥1.05 Billion CN¥589.28 Million CN¥343.36 Million CN¥337.57 Million
Research & Development CN¥251.92 Million CN¥227.45 Million CN¥124.89 Million CN¥69.47 Million CN¥63.09 Million
SG&A CN¥164.58 Million CN¥277.16 Million CN¥210.60 Million CN¥152.02 Million CN¥137.90 Million
Total Operating Expenses CN¥1.54 Billion CN¥601.53 Million CN¥399.62 Million CN¥218.50 Million CN¥209.26 Million
Operating Income CN¥400.05 Million CN¥448.22 Million CN¥189.67 Million CN¥124.85 Million CN¥128.31 Million
EBITDA CN¥553.78 Million CN¥675.49 Million CN¥320.99 Million CN¥231.35 Million CN¥213.64 Million
EBIT CN¥351.90 Million CN¥473.60 Million CN¥189.21 Million CN¥132.60 Million CN¥132.01 Million
Interest Expense CN¥65.46 Million CN¥35.10 Million CN¥16.09 Million CN¥9.44 Million CN¥6.28 Million
Income Before Tax CN¥351.90 Million CN¥438.50 Million CN¥173.13 Million CN¥123.16 Million CN¥125.73 Million
Income Tax Expense CN¥24.90 Million CN¥38.69 Million CN¥7.67 Million CN¥387.71K CN¥16.92 Million
Net Income CN¥327.00 Million CN¥404.39 Million CN¥162.94 Million CN¥129.11 Million CN¥115.39 Million

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Sinopep-Allsino Biopharmaceutical Co. Ltd. A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets CN¥6.74 Billion CN¥5.08 Billion CN¥3.55 Billion CN¥2.52 Billion CN¥2.13 Billion
Total Current Assets CN¥2.51 Billion CN¥2.01 Billion CN¥1.49 Billion CN¥1.05 Billion CN¥1.10 Billion
Cash & Equivalents — — — — —
Short-term Investments CN¥116.00 Million CN¥208.00 Million — CN¥43.01 Million CN¥87.13 Million
Net Receivables CN¥500.68 Million CN¥547.13 Million CN¥300.53 Million CN¥252.48 Million CN¥143.37 Million
Inventory CN¥859.52 Million CN¥584.04 Million CN¥377.17 Million CN¥323.48 Million CN¥250.82 Million
Property, Plant & Equipment — — — — —
Goodwill CN¥156.34 Million CN¥156.34 Million CN¥156.34 Million CN¥156.34 Million CN¥160.92 Million
Total Liabilities CN¥3.74 Billion CN¥2.40 Billion CN¥1.36 Billion CN¥597.41 Million CN¥318.14 Million
Total Current Liabilities CN¥2.16 Billion CN¥1.75 Billion CN¥973.34 Million CN¥551.32 Million CN¥275.40 Million
Long-term Debt CN¥1.32 Billion CN¥445.21 Million CN¥286.49 Million — —
Net Debt CN¥1.43 Billion CN¥943.38 Million CN¥100.61 Million CN¥-79.77 Million CN¥-508.23 Million
Total Stockholder Equity CN¥2.99 Billion CN¥2.66 Billion CN¥2.17 Billion CN¥1.91 Billion CN¥1.81 Billion
Retained Earnings CN¥809.45 Million CN¥722.41 Million CN¥464.61 Million CN¥359.95 Million CN¥266.30 Million

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Sinopep-Allsino Biopharmaceutical Co. Ltd. A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow CN¥681.24 Million CN¥400.12 Million CN¥350.21 Million CN¥29.29 Million CN¥180.75 Million
Capital Expenditures CN¥1.37 Billion CN¥1.09 Billion CN¥660.64 Million CN¥438.36 Million CN¥233.36 Million
Free Cash Flow CN¥-685.77 Million CN¥-690.01 Million CN¥-310.43 Million CN¥-409.07 Million CN¥-52.61 Million
Investing Cash Flow — CN¥-1.39 Billion CN¥-662.21 Million CN¥-449.74 Million CN¥-236.93 Million
Financing Cash Flow — CN¥799.75 Million CN¥631.90 Million CN¥236.91 Million CN¥534.89 Million
Dividends Paid CN¥239.60 Million CN¥118.75 Million CN¥57.61 Million CN¥31.98 Million CN¥6.04 Million
Stock-Based Compensation — — — CN¥460.80K CN¥5.79 Million
Depreciation CN¥317.94 Million CN¥210.01 Million CN¥135.55 Million CN¥99.96 Million CN¥84.77 Million
Change in Cash CN¥309.45 Million CN¥-184.98 Million CN¥316.69 Million CN¥-184.35 Million CN¥477.13 Million

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Earnings History — EPS Actual vs. Analyst Estimates

Track Sinopep-Allsino Biopharmaceutical Co. Ltd. A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Apr 29, 2026 0.39 0.29 +34.48%
Oct 22, 2025 0.34 0.41 -17.07%
Aug 20, 2025 0.30 0.57 -47.37%
Apr 21, 2023 0.10 — —
Feb 27, 2023 0.36 — —
Oct 24, 2022 0.09 — —
Aug 29, 2022 0.08 — —
Apr 27, 2022 0.08 — —